[go: up one dir, main page]

ATE251901T1 - Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson - Google Patents

Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson

Info

Publication number
ATE251901T1
ATE251901T1 AT01111109T AT01111109T ATE251901T1 AT E251901 T1 ATE251901 T1 AT E251901T1 AT 01111109 T AT01111109 T AT 01111109T AT 01111109 T AT01111109 T AT 01111109T AT E251901 T1 ATE251901 T1 AT E251901T1
Authority
AT
Austria
Prior art keywords
parkinson
therapeutic system
transdermal therapeutic
rotigotin
achievement
Prior art date
Application number
AT01111109T
Other languages
English (en)
Inventor
Thomas Dr Lauterbach
Dietrich Wilhelm Schacht
Hans-Michael Dr Wolff
Walter Dr Mueller
Original Assignee
Sanol Arznei Schwarz Gmbh
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE251901(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh, Lohmann Therapie Syst Lts filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of ATE251901T1 publication Critical patent/ATE251901T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Elements Other Than Lenses (AREA)
  • Radiation-Therapy Devices (AREA)
  • Steroid Compounds (AREA)
AT01111109T 2001-05-08 2001-05-08 Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson ATE251901T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111109A EP1256339B1 (de) 2001-05-08 2001-05-08 Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson

Publications (1)

Publication Number Publication Date
ATE251901T1 true ATE251901T1 (de) 2003-11-15

Family

ID=8177356

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01111109T ATE251901T1 (de) 2001-05-08 2001-05-08 Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson
AT02740569T ATE444061T1 (de) 2001-05-08 2002-05-06 Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin- plasmaspiegeln

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02740569T ATE444061T1 (de) 2001-05-08 2002-05-06 Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin- plasmaspiegeln

Country Status (15)

Country Link
EP (3) EP1256339B1 (de)
JP (2) JP5026656B2 (de)
KR (1) KR100974974B1 (de)
CN (2) CN102172351B (de)
AT (2) ATE251901T1 (de)
CY (1) CY1109861T1 (de)
DE (2) DE60100994T2 (de)
DK (2) DK1256339T3 (de)
ES (2) ES2204780T3 (de)
HK (1) HK1049444B (de)
HU (1) HU229350B1 (de)
PT (2) PT1256339E (de)
RU (1) RU2272625C2 (de)
WO (1) WO2002089778A2 (de)
ZA (1) ZA200209982B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DK1256340T3 (da) * 2001-05-08 2003-12-01 Sanol Arznei Schwarz Gmbh Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (de) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasale formulierung enthaltend
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1796610A4 (de) * 2004-09-29 2012-12-05 Schwarz Pharma Inc Transdermales therapeutisches system für parkinson-krankheit
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
WO2011048491A2 (en) * 2009-10-19 2011-04-28 Actavis Group Ptc Ehf Amorphous rotigotine co-precipitates
SMT202400353T1 (it) 2009-12-22 2024-11-15 UCB Biopharma SRL Polivinilpirrolidone per la stabilizzazione di una dispersione solida della forma non cristallina della rotigotina
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
CA2948220C (en) 2014-05-20 2023-06-20 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
EP3145503A1 (de) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Verfahren zur anpassung der freisetzung eines wirkstoffs in einem transdermalen abgabesystem
KR102364378B1 (ko) * 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
DE102014114282A1 (de) 2014-10-01 2016-04-07 Neuraxpharm Arzneimittel Gmbh Transdermales therapeutisches System mit Rotigotin zur Behandlung von Morbus Parkinson
KR102279552B1 (ko) 2016-12-28 2021-07-19 히사미쓰 세이야꾸 가부시키가이샤 부토르파놀 함유 첩부제
DE102018120505A1 (de) * 2017-10-20 2019-04-25 Amw Gmbh Verhinderung der Kristallisation von Wirkstoffen in transdermalen Darreichungssystemen
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751515B2 (ja) * 1986-09-10 1995-06-05 明治製菓株式会社 経皮吸収製剤
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten

Also Published As

Publication number Publication date
HK1049444A1 (en) 2003-05-16
EP1256339B1 (de) 2003-10-15
ATE444061T1 (de) 2009-10-15
DK1256339T3 (da) 2004-02-09
JP2004536054A (ja) 2004-12-02
DE60100994T2 (de) 2004-07-22
HUP0500525A2 (hu) 2005-09-28
CN102172351A (zh) 2011-09-07
KR100974974B1 (ko) 2010-08-09
JP5026656B2 (ja) 2012-09-12
ZA200209982B (en) 2003-03-24
PT1256339E (pt) 2004-02-27
CN1606435A (zh) 2005-04-13
WO2002089778A3 (en) 2004-08-19
JP2010106037A (ja) 2010-05-13
WO2002089778A2 (en) 2002-11-14
RU2272625C2 (ru) 2006-03-27
ES2204780T3 (es) 2004-05-01
EP1471892A2 (de) 2004-11-03
PT1471892E (pt) 2009-12-23
ES2331787T3 (es) 2010-01-15
EP1471892B1 (de) 2009-09-30
KR20030016373A (ko) 2003-02-26
CN102172351B (zh) 2013-07-17
HU229350B1 (en) 2013-11-28
DE60233898D1 (de) 2009-11-12
EP1256339A1 (de) 2002-11-13
DK1471892T3 (da) 2009-12-07
DE60100994D1 (de) 2003-11-20
EP1344522A1 (de) 2003-09-17
RU2003133217A (ru) 2005-04-20
HK1049444B (zh) 2004-03-19
CY1109861T1 (el) 2014-09-10

Similar Documents

Publication Publication Date Title
ATE251901T1 (de) Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson
PT1256340E (pt) Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
WO2002041883A3 (en) As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
AU1046202A (en) Transdermal therapeutic system for treating restless-legs-syndrome
ATE493981T1 (de) Einmal tägliche dosierformen von trospium
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
DE60211139D1 (de) Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
SE0102147D0 (sv) New methods
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE602004025040D1 (de) Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
TR200301916T4 (tr) Rotigotinin yüksek plazma seviyelerini kapsayan parkinson hastalığına yönelik transdermal terapötik sistem.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1256339

Country of ref document: EP

EEIH Change in the person of patent owner